AbbVie (NYSE: ABBV), which completed the acquisition of Allergan on May 8, 2020, reported second quarter 2020 earnings results today. The company’s adjusted earnings and revenue in Q2 bettered the market’s estimates. which included a partial quarter of Allergan and COVID-19 pandemic impact.
ABBV stock was trading up about 2% in the before market hours.
On an adjusted basis, earnings increased to $2.34 per share from $2.26 per share in the year-ago quarter. On a GAAP basis, AbbVie posted a loss of $0.46 per share compared to a profit of $0.49 per share in the second quarter of 2019.
Revenues of $10.425 billion, increased 26.3% on a reported basis, and decreased 5.3% on a comparable operational basis, due to the COVID-19 pandemic.
AbbVie provided combined company earnings outlook for fiscal 2020, which includes the results of Allergan from May 8, 2020 through December 31, 2020. The company now expects GAAP EPS to be in the range of $4.12 to $4.22. On a non-GAAP basis, profit is now expected to be in the range of $10.35 to $10.45 per share.
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related